Session I: Cancer of the Pancreas and Biliary Tract
Hereditary Pancreatic Cancer: Genetics & Surveillance
Targeting the Microenvironment and the Immune System
How to Integrate and Interpret Best Imaging in Locally Advanced PDAC and What to Use for Response Evaluation: EUS, PET/CT, MRI
Debate: Neoadjuvant Treatment for Resectable Pancreatic Cancer. Yes vs. No
Treatment Modalities for Locally Advanced Pancreatic Cancer (including SBRT, ablation,)
The Actual Algorithm in Advanced PDAC: A Strategic Approach (covering later lines, PARP)
Druggable Molecular Alterations in Bile Duct Cancer
Locally Advanced Bile Duct Cancer
Session II: Progress in GI Cancer
How can Consortia contribute to the Progress in GI Oncology? Contribution of the ARCAD group
How can Consortia contribute to the Progress in GI Oncology? Contribution of the ACCENT group
Teaching and Interpreting Statistics for Clinicians
Reporting on Endpoints: The Example in CRC
Session III: Esophageal and Gastric Cancers
When and How to Treat Early Esophageal Cancer Endoscopically (covering EMR, ESD, RFA)
Debate: GEJ Cancer: Locally Advanced Perioperative CT or Preoperative CRT. Pro Chemo vs. Pro Neoadjuvant CRT
Adjuvant Treatment After Preoperative CRT in Esophageal or GEJ Cancer: When and How?
Interaction Between Neoadjuvant Therapies, Comorbidity and Surgery
Session IV: Gastric Cancer
Treatment Algorithms in Metastatic Gastric Cancer
New HER2-Directed Agents in Gastric Cancer
Session V: Impact of Patient Factors in Disease Biology in GI Cancer: Gender and Age
The Explosion of CRC (or GI Cancer) in Young Adults: Why?
Why Does Gender Matter for Treatment?
Session VI: Relevant Pathways in GI Cancer: How Relevant and How to Approach Them
The HER2 Pathway in GI Cancer
FGFR and Other Fusions in GI Cancer
Should DPD Deficiency be Tested Before Starting 5FU?
How to Interpret an NGS Sequencing Report?
Tumor or Liquid Biopsies in the Future? Pro Tumor vs. Liquid Biopsies; Discussion
Session VII: Keynote Presentations
Keynote Lecture: Integrating Health Economic Evaluation into Daily Practice in the COVID-19 Era
Keynote Lecture: New Promising PET Tracers
Session VIII: Hepatocellular Cancer
Can We Maximize the Benefit of IO in HCC
Locoregional Treatment in HCC
Liver Transplantation in the COVID-19 Era
Session IX: Multimodality Therapy for Rectal Cancer
Neoadjuvant Treatment: How and for Whom?
Organ Preserving Strategy
Local excision (TEM/TAM) vs Radical Resection – When and in Whom?
Session X: Immune Mechanisms and Immune Therapy in GI Cancer
Biomarkers for Checkpoint Inhibitors in GI cancer
How Can We Increase the Immunogenicity in MSS CRC?
The Link Between the Immune Microenvironment and Outcomes in Colorectal Cancer
New immunotherapy combinations (anti VEGF + CPi; CART; TKIs + CPi) in GI cancers
Session XI: Molecular Biology in Colorectal Cancer
Liver Transplantation in GI Cancer: A Reality or An Illusion? The Case in NET, Cholangiocarcinoma, and CRC
Genetic Risk Factors for GI Cancers/Hereditary Syndromes
Session XII: Colorectal Cancer
Treatment Algorithm in mCRC: How to Select First-Line Therapy?
Treatment Algorithm in mCRC: Later Lines
Adjuvant Treatment for Stage II-III Colon Cancer
Session XIII: New Breakthroughs in Rare Cancers
What is New in GIST in the Last 12 Months?
What is New in Pancreatic NETs in the Last 12 Months?
What is New in Non-Pancreatic NETs in the Last 12 Months?
What is New on Debulking and HIPEC in Peritoneal Carcinomatosis in the Last 12 Months?